Ernexa Therapeutics Inc. (ERNA) Stock

Ernexa Therapeutics Inc. (ERNA) is a Healthcare stock trading at $4.78 (as of 2026-08-21), with a market capitalization of $2.90M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Ernexa Therapeutics Inc. is a preclinical-stage company developing iMSC cell therapies for solid tumors and autoimmune diseases. Its programs include ERNA-101 for ovarian cancer and ERNA-102 for rheumatoid arthritis, and it also has a license agreement with Factor Bioscience Limited.

Valuation — source: SEC EDGAR (first-party)
Price$4.78
Market Cap$2.90M
DCF Value (model)$-235.05
DCF Upside vs Price-5017.4%
Financial Health — source: SEC EDGAR
Altman Z-Score-69.78 (distress)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderBleichroeder LP ($398000.00)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryBiotechnology
CEOSanjeev Luther
Employees6
CountryUS
IPO Date1991-08-29

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Genprex, Inc. (GNPX)
  • 60 Degrees Pharmaceuticals, Inc. (SXTP)
  • Nexentis Technologies Inc. (NXTS)
  • Onconetix, Inc. (ONCO)
  • HCW Biologics Inc. (HCWB)
  • Oragenics, Inc. (OGEN)
  • CDT Equity Inc. (CDT)
  • Shuttle Pharmaceuticals Holdings, Inc. (SHPH)
ERNA earnings history · ERNA institutional & insider holders · ERNA KPIs & operating metrics · ERNA financials · ERNA investor presentations & press releases · ERNA SEC filings · ERNA peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.